Baylor College of Medicine

Tvardi Therapeutics, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

The United States of America National Institute of Health (nih)

David John Tweardy

William E Bauta

William R Cantrell, Jr

Moses M Kasembeli

Marvin X Xu

Sofia De Achaval

Thomas Kristian Eckols

Xuejun Xu

Sandeep K Agarwal

Mesias Pedroza

Claire E Bocchini

Josh Milner

Sofia De Achaval Wied

Marvin Xu

Thomas Eckols

Compounds as STAT3 inhibitors are described. A pharmaceutical composition comprising the same, methods of making the same, and a method for treating or preventing conditions such as cancer, chronic inflammation, and fibrosis using the same, are described.

STAT3 inhibitors

Embodiments of the invention include methods of treating, preventing, and/or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness, cachexia, and a combination thereof in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction in the risk of muscle wasting. In at least particular cases, the small molecules are inhibitors of STAT3.

Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia

Embodiments of the invention include methods of treating, preventing, and/or reducing the risk of fibrosis in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction of the risk of fibrosis. In at least particular cases, the small molecules are inhibitors of STAT3.

Methods and compositions for treatment of fibrosis

Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well as their derivatives. Methods of screening additional compounds for Stat3 inhibition activity and/or non-inhibition of Stat1 activity are also described herein.

Stat3 inhibitors

Growing community of inventors

Houston, TX, United States of America

David John Tweardy